08:00 AM EDT, 10/16/2024 (MT Newswires) -- Abbott Laboratories ( ABT ) reported Q3 adjusted earnings Wednesday of $1.21 per diluted share, up from $1.14 a year earlier.

Analysts polled by Capital IQ expected $1.20.

Net sales for the quarter ended Sept. 30 were $10.64 billion, up from $10.14 billion a year earlier.

Analysts surveyed by Capital IQ expected $10.55 billion.

For Q4, the pharmaceuticals giant expects adjusted earnings of $1.31 to $1.37 per diluted share. Analysts polled by Capital IQ expect $1.34.

For 2024, the company now expects adjusted earnings of $4.64 to $4.70 per diluted share, compared with its previous guidance for $4.61 to $4.71. Analysts polled by Capital IQ expect $4.66.

Additionally, the board has approved a new share repurchase program of up to $7 billion of the company's common shares.

Price: 115.91, Change: -0.14, Percent Change: -0.12